Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update.

• Autor(a) principal: Fonseca, João Eurico
• Data de Publicação: 2010
• Outros Autores: Canhão, Helena, Reis, Paulo, Santos, Maria José, Branco, Jaime, Quintal, Alberto, Malcata, Armando, Araújo, Domingos, Ventura, Francisco, Figueiredo, Guilherme, da Silva, José Canas, Patto, José Vaz, Queiroz, Mário Viana, Santos, Rui André, Neto, Adriano José, de Matos, J. Alves, Maria Rodrigues, Ana, Mourão, Ana Filipa, Ribeiro, Ana Sofia, Cravo, Ana Rita, Barcelos, Anabela, Cardoso, Anabela, Vilar, António, Braña, Arecili, Faustino, Augusto, Silva, Candida, Godinho, Fátima, Cunha, Inês, Costa, José António, Gomes, José António Melo, Pinto, José António Araújo, da Silva, José António Pereira, Miranda, Luís Cunha, Inês, Luís Sousa, Santos, Luís Maurício, Cruz, Margarida, Salvador, Maria João, Ferreira, Maria Júlia, Rial, Maria, Bernardes, Miguel, Bogas, Mónica, Araújo, Paula, Machado, Pedro, Pinto, Patrícia, de Melo, Rui Gomes, Cortes, Sara, Alcino, Sérgio, Capela, Susana
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://www.scopus.com/inward/record.url?scp=77957598053&partnerID=8YFLogxK
• topic: Artrite Reumatóide; Terapêutica Biológica; Anti-TNF; Rituximab; Abatacept; Tocilizumab; Rheumatology

The authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of rheumatoid arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the contraindications and procedures in the case of non-responders. Biological treatment should be considered in RA patients with a disease activity score 28 (DAS 28) superior to 3.2 despite treatment with 20mg/week of methotrexate (MTX) for at least 3 months or, if such treatment is not possible, after 6 months of other conventional disease modifying drug or combination therapy. A DAS 28 score between 2.6 and 3.2 with a significant functional or radiological deterioration under treatment with conventional regimens could also constitute an indication for biological treatment. The treatment goal should be remission or, if that is not achievable, at least a low disease activity, characterized by a DAS28 lower than 3.2, without significative functional or radiological worsening. The response criteria, at the end of the first 3 months of treatment, are a decrease of 0.6 in the DAS28 score. After 6 months of treatment response criteria is defined as a decrease of more than 1.2 in the DAS28 score. Non-responders, in accordance to the Rheumatologist's clinical opinion, should try a switch to another biological agent (tumour necrosis factor antagonist, abatacept, rituximab or tocilizumab).